Trials / Withdrawn

WithdrawnNCT03070132

802NP301 Efficacy and Safety Study of BIIB074 in Participants With Trigeminal Neuralgia

A Phase 3 Placebo-Controlled, Double-Blind Randomized Withdrawal Study to Evaluate the Efficacy and Safety of BIIB074 in Subjects With Trigeminal Neuralgia

Status: Withdrawn
Phase: Phase 3
Study type: Interventional
Enrollment: 0 (actual)

Sponsor: Biogen · Industry
Sex: All
Age: 18 Years
Healthy volunteers: Not accepted

Summary

The primary objective of the study is to evaluate the efficacy of BIIB074 in treating pain experienced by participants with trigeminal neuralgia (TN). Secondary objectives of this study are to investigate the safety and tolerability of BIIB074 in participants with TN and to evaluate the population pharmacokinetics (PK) of BIIB074.

Conditions

Trigeminal Neuralgia

Interventions

Type	Name	Description
DRUG	BIIB074	Administered as specified in the treatment arm
DRUG	Placebo	Matched placebo

Timeline

Start date: 2023-04-19
Primary completion: 2025-10-14
Completion: 2026-08-21
First posted: 2017-03-03
Last updated: 2023-05-06

Regulatory

FDA-regulated drug study

Source: ClinicalTrials.gov record NCT03070132. Inclusion in this directory is not an endorsement.